WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584506
CAS#: 20098-14-0
Description: Idramantone is an immunostimulant, a derivative of adamantine, and used in the treatment of pulmonary tuberculosis patients.
Hodoodo Cat#: H584506
Name: Idramantone
CAS#: 20098-14-0
Chemical Formula: C10H14O2
Exact Mass: 166.10
Molecular Weight: 166.220
Elemental Analysis: C, 72.26; H, 8.49; O, 19.25
Synonym: Idramantone; Kemantane
IUPAC/Chemical Name: 5-Hydroxy-2-adamantanone
InChi Key: TZBDEVBNMSLVKT-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H14O2/c11-9-7-1-6-2-8(9)5-10(12,3-6)4-7/h6-8,12H,1-5H2
SMILES Code: O=C1C2CC3CC(C2)(O)CC1C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 166.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Boĭko SS, Zherdev VP, Kisliak NA, Piatin BM, Klimova NV, Glan PV, Dvorianinov AA. [Interspecific differences in kemantan pharmacokinetics]. Eksp Klin Farmakol. 1994 Nov-Dec;57(6):48-50. Russian. PubMed PMID: 7756963.
2: Boĭko SS, Zherdev VP, Kisliak NA. [The clinical pharmacokinetics of kemantane]. Farmakol Toksikol. 1991 Jan-Feb;54(1):57-9. Russian. PubMed PMID: 1860503.
3: Man'ko VM, Pinegin BV, Rudneva TB, Zavgorodniĭ SG, Blagonravova OL, Gadzhiev RI, Artsimovich NG. [The effect of kemantane on T-helpers and T-suppressors]. Zh Mikrobiol Epidemiol Immunobiol. 1991 Sep;(9):66-7. Russian. PubMed PMID: 1836926.
4: Boĭko SS, Zherdev VP, Dvorianinov AA, Janku I, Buchar E. [Kemantane pharmacokinetics in rats]. Biull Eksp Biol Med. 1990 Nov;110(11):501-3. Russian. PubMed PMID: 2083333.
5: Man'ko VM, Pinegin BV, Rudneva TB, Blagonravova OL, Artsimovich NG, Gadzhiev RI. [The mitostatic and lymphotoxic action of kemantane and its effect on B-suppressors]. Zh Mikrobiol Epidemiol Immunobiol. 1991 Jun;(6):63-5. Russian. PubMed PMID: 1832260.
6: Kossii NV, Khomenko IS, Gergert VIa. [Treatment of immunodeficient conditions caused by viral infection with the Soviet immunomodulator kemantan in patients with pulmonary tuberculosis]. Probl Tuberk. 1991;(6):23-6. Russian. PubMed PMID: 1780303.
7: Rekalova EM. [The immunomodulator kemantan in the treatment of patients with exacerbated chronic obstructive bronchitis]. Lik Sprava. 1992 Apr;(4):73-6. Russian. PubMed PMID: 1441384.
8: Kovalev IE, Shipulina NV. Effect of adamantanone derivative possessing anti-HIV properties on the redox processes in the cytochrome P-450 system. Dokl Biochem Biophys. 2001 May-Jun;378:210-3. PubMed PMID: 11712183.